|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Phase II Combination Chemotherapy with VIP (VP-16/IPP/CACP) for Refractory Hodgkin's and non-Hodgkin's Lymphoma
Basic Trial Information
Objectives I. Determine the objective response and duration of response of patients with refractory Hodgkin's and non-Hodgkin's lymphomas treated with the combination VIP (cis-platinum/VP-16213/ifosfamide). II. Determine the toxicity associated with this combination in these patients. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients with measurable, biopsy-proven non-Hodgkin's lymphoma or Hodgkin's disease refractory to standard combination chemotherapy. Hodgkin's disease must be refractory to MOPP, BCVPP, or ABVD with or without CCNU; patients with non-Hodgkin's lymphomas of favorable histologies must be resistant to COP or chlorambucil. Patients with non-Hodgkin's lymphomas of unfavorable histology must have relapsed after CHOP therapy. Patients must have recovered from previous myelosuppressive chemotherapy, have a serum creatinine of less than 2.0 g/dl or a creatinine clearance of greater than 50 mg/minute, and have a performance status of at least 50 percent. Expected Enrollment If there is any response among the first 9 patients in each histologic category, accrual in that category will be continued to 25 patients. Outline Nonrandomized study. 3-Drug Combination Chemotherapy. VIP: VP-16213, VP-16, NSC-141540; Ifosfamide, IPP, NSC-109724; cis-Platinum, CACP, NSC-119875; N-Acetylcysteine, NAC, NSC-111180. Trial Lead Organizations Indiana University Melvin and Bren Simon Cancer Center
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |